Center for Biological Diversity
FDANonrulemakingFDA-2025-P-5436

Requests that the FDA revoke its actions to approve the Abbreviate New Drug Application 216616, a generic version of Mifepristone, and modify the associated regimen (including the REMS) until the agency conducts the required consultation with the United States Fish and Wildlife Service (FWS) and National Marine Fisheries Service (NMFS) (collectively, “the Services”) as compelled by the ESA

RIN
Last modified
Oct 17, 2025
Comment window
Center for Biological Diversity filings
1

Activity

Center for Biological Diversity filed 1 comment on this docket between Jul 15, 2026 and Jul 15, 2026. 1 other organizations filed here.

What Center for Biological Diversity filed (1)

Abstract

Open

View on regulations.gov →